Download full-text PDF |
Source |
---|
Sci Rep
January 2025
Ministry of Health, Ankara Ottoman Oral and Dental Health Center, Ankara, Turkey.
Chlorhexidine (CHX) is the most commonly used mouthwash with proven antiplaque and antibacterial activity. The aim is to evaluate the effect of vitamin C (VitC) in CHX mouthwash on plaque accumulation and gingivitis, and to compare it with CHX alone mouthwash and antiseptic phenol-containing mouthwashes. This study conducted as a multicenter, randomized, controlled, double-blind, parallel design clinical study.
View Article and Find Full Text PDFFarm Hosp
January 2025
Servicio de Farmacia, Hospital Universitario La Plana, Castellón, España.
Background: Adalimumab biosimilar MSB11022 (Idacio®) has been approved for the same indications as its originator (Humira®), based on findings from clinical trials in plaque psoriasis. Data on its efficacy and safety in inflammatory bowel disease, however, are scarce.
Methods: Retrospective, observational study of 44 patients with inflammatory bowel disease: 30 were treated with originator adalimumab, five were directly started on MSB11022, and nine switched from originator to biosimilar adalimumab.
J Transl Med
January 2025
Department of Life, Health & Environmental Sciences, University of L'Aquila, Building Rita Levi Montalcini, Coppito, L'Aquila, 67100, Italy.
Background: A growing number of in vitro and in vivo studies suggest the application of probiotics as a natural approach to maintaining oral health. This double-blind, randomized controlled trial aimed to evaluate the efficacy of Levilactobacillus brevis CD2 (CNCM I-5566), a multifunctional probiotic frequently used in oral medicine, in preserving or improving several recognized oral health indicators.
Methods: Thirty consenting healthy adults were randomized to receive four lozenges per day of L.
Front Neurol
January 2025
Department of Radiology, The First People's Hospital of Lianyungang, Lianyungang Clinical College of Nanjing Medical University, Lianyungang, China.
Objective: To develop a deep learning (DL) model for carotid plaque detection based on CTA images and evaluate the clinical application feasibility and value of the model.
Methods: We retrospectively collected data from patients with carotid atherosclerotic plaques who underwent continuous CTA examinations of the head and neck at a tertiary hospital from October 2020 to October 2022. The model combined ResUNet with the Pyramid Scene Parsing Network (PSPNet) to enhance plaque segmentation.
Co-existing neuropathological comorbidities have been repeatedly reported to be extremely common in subjects dying with dementia due to Alzheimer disease. As these are likely to be additive to cognitive impairment, and may not be affected by molecularly-specific AD therapeutics, they may cause significant inter-individual response heterogeneity amongst subjects in AD clinical trials. Furthermore, while originally noted for the oldest old, recent reports have now documented high neuropathological comorbidity prevalences in younger old AD subjects, who are more likely to be included in clinical trials.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!